CERVO

CervoMed is a clinical-stage biotechnology company focused on treatments for age-related neurologic and neurodegenerative disorders. Its lead and essentially sole disclosed program is neflamapimod, an orally administered, brain-penetrant small molecule inhibitor of p38 alpha designed to address synaptic dysfunction and neuronal injury. The company is primarily advancing neflamapimod in dementia with Lewy bodies, where it has reported Phase 2b data and has described a finalized Phase 3 trial design aligned with global regulators. CervoMed originated from EIP Pharma and became a public company through the 2023 merger with Diffusion Pharmaceuticals, after which the combined company adopted the CervoMed name. The company is based in Boston and remains focused on CNS diseases with a narrow pipeline centered on neflamapimod.